SCHEMBL1852110

SCHEMBL1852110

O=c1[nH]c(NCCO)nc2c1oc1ccc(Br)cc12

nearest known ligand 0.57

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CSNK2B P67870 20/20 0.57
PIM1 P11309 19/20 0.57
CSNK2A2 P19784 14/20 0.57
PIM3 Q86V86 13/20 0.57
PIM2 Q9P1W9 13/20 0.57
CDC7 O00311 10/20 0.57
CSNK2A1 P68400 10/20 0.57
CYP1A2 P05177 1/20 0.51
CSNK2A3 Q8NEV1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1849817 0.89 CSNK2B (0.57) CSNK2BPIM1CSNK2A2PIM3PIM2
SCHEMBL1856871 0.87 PIM1 (0.53) CSNK2BPIM1CSNK2A2PIM3PIM2
SCHEMBL12661260 0.86 CSNK2B (0.42) CSNK2BPIM1CSNK2A2PIM3PIM2
SCHEMBL1850526 0.86 CSNK2B (0.53) CSNK2BPIM1CSNK2A2PIM3PIM2
SCHEMBL13650760 0.81 CSNK2B (0.48) CSNK2BPIM1CSNK2A2PIM3PIM2
SCHEMBL1852949 0.78 CSNK2B (0.58) CSNK2BPIM1CSNK2A2PIM3PIM2
SCHEMBL1850361 0.76 CSNK2B (0.61) CSNK2BPIM1CSNK2A2PIM3PIM2
SCHEMBL1851424 0.76 CSNK2B (0.61) CSNK2BPIM1CSNK2A2PIM3PIM2
SCHEMBL1856877 0.75 CSNK2B (0.67) CSNK2BPIM1CSNK2A2PIM3PIM2
SCHEMBL12661564 0.75 CSNK2B (0.67) CSNK2BPIM1CSNK2A2PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP claimed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US claimed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP claimed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO claimed
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 CSNK2B 350/4885PIM1 1977/4885CSNK2A2 906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.